The development of atherosclerotic arterial lesions in response to elevated levels of circulating lipids is characterized by inflammatory activation of the vascular wall and is associated with the induction of innate and adaptive immune responses directed, at least in part, toward (modified) lipoproteins 1,2 . More specifically, B-lymphocytedependent immune responses play prominent roles in atherosclerosis. B1 cell-derived natural IgM antibodies have consistently been shown to be atheroprotective (reviewed in refs. 3,4). In contrast, B2 cell responses promote atherogenesis 5-8 through their support of proatherogenic T cells 5 . Regulatory B cells originate from the B2 cell compartment and are involved in the control of exaggerated adaptive immune responses 9-11 . However, their developmental pathway is not well understood, and their contribution to atherosclerosis is still uncertain 12, 13 . Importantly, there are two major B2 cell subsets, follicular (FOB) and MZB cells, with distinct developmental pathways and functional properties 14 . Although the contribution of adaptive FOB cells to the development of atherosclerosis can be inferred from their roles in the support of proatherogenic T FH cells and germinal center (GC) responses 15 , the potential contribution of innate-like MZB cells to regulation of the immune response to HCD cannot easily be predicted and remains almost unexplored, apart from the reported ability of this B2 cell subset to mount T cell-independent responses to (modified) lipoproteins (for example, oxidized phosphatidylcholine epitopes) 16 .
The development of atherosclerotic arterial lesions in response to elevated levels of circulating lipids is characterized by inflammatory activation of the vascular wall and is associated with the induction of innate and adaptive immune responses directed, at least in part, toward (modified) lipoproteins 1,2 . More specifically, B-lymphocytedependent immune responses play prominent roles in atherosclerosis. B1 cell-derived natural IgM antibodies have consistently been shown to be atheroprotective (reviewed in refs. 3,4). In contrast, B2 cell responses promote atherogenesis [5] [6] [7] [8] through their support of proatherogenic T cells 5 . Regulatory B cells originate from the B2 cell compartment and are involved in the control of exaggerated adaptive immune responses [9] [10] [11] . However, their developmental pathway is not well understood, and their contribution to atherosclerosis is still uncertain 12, 13 . Importantly, there are two major B2 cell subsets, follicular (FOB) and MZB cells, with distinct developmental pathways and functional properties 14 . Although the contribution of adaptive FOB cells to the development of atherosclerosis can be inferred from their roles in the support of proatherogenic T FH cells and germinal center (GC) responses 15 , the potential contribution of innate-like MZB cells to regulation of the immune response to HCD cannot easily be predicted and remains almost unexplored, apart from the reported ability of this B2 cell subset to mount T cell-independent responses to (modified) lipoproteins (for example, oxidized phosphatidylcholine epitopes) 16 .
RESULTS

MZB cells limit the development of atherosclerosis through inhibition of the T FH response
To address the role of MZB cells in atherosclerosis, we generated mice with B cell lineage-specific (Cd79a Cre/+ ) conditional deletion of the gene Rbpj (also known as Rbpjk) (Rbpjk flox/flox ), which encodes the effector transcription factor downstream of the Notch2 receptor and is known to be required for MZB cell development [17] [18] [19] . We then reconstituted lethally irradiated LDL receptor-deficient (Ldlr −/− ) mice with bone marrow (BM) from either Cd79a Cre/+ ; Rbpjk flox/flox mice or Cd79a +/+ ; Rbpjk flox/flox controls. After recovery, the mice were put on an HCD for 8 or 16 weeks. In Cd79a Cre/+ ; Rbpjk flox/flox mice, disruption of Notch signaling in B cells induced a selective depletion of splenic MZB cells ( Fig. 1a and Supplementary Fig. 1a ) and markedly accelerated the development of both early ( Fig. 1b and Supplementary  Fig. 1b ) and advanced ( Fig. 1c) atherosclerotic lesions as compared to control mice, despite not having effects on plasma lipid parameters ( Supplementary Fig. 1c-f) . Analysis of plaque composition showed sustained accumulation of macrophages and CD3 + T cells in the lesions of MZB cell-deficient mice ( Supplementary Fig. 1g-j) . We detected only subtle changes in antibody responses against modified LDL (Supplementary Fig. 1k-n) , which could not account for the marked acceleration of atherosclerosis in MZB cell-deficient a r t i c l e s 6 0 2 VOLUME 23 | NUMBER 5 | MAY 2017 nature medicine animals. The abundance of neutrophils ( Supplementary Fig. 2a ) and monocytes/macrophages ( Supplementary Fig. 2b ,c) in the spleen was similar for MZB cell-deficient and control mice. We therefore assessed the effect of MZB cell deficiency on peripheral T cell activation status and found that MZB cell-deficient mice had increased percentages of splenic CD4 + T effector memory (CD44 hi CD62L − ) cells ( Fig. 2a) and T helper type 2 (T H 2) cells ( Supplementary  Fig. 2d ), with a trend toward an increased percentage of T helper type 1 (T H 1) cells but no change in the percentages of T helper type 17 (T H 17) and regulatory T cells ( Supplementary Fig. 2e-g ), as compared to control mice. Intriguingly, we also found a substantial accumulation of T FH cells (CD4 + CXCR5 hi PD1 hi ) in the spleens of MZB cell-deficient mice (Fig. 2b) , whereas the percentage of T FH cells was not significantly higher in the lymph nodes of MZB cell-deficient as compared to control mice (1.78 ± 0.4% of CD4 + T cells, n = 7 versus 0.93 ± 0.18%, n = 8, respectively; P = 0.061). Ldlr −/− mice reconstituted with Cd79a Cre/+ BM did not show an increase in T FH cell numbers or atherosclerotic lesion size after 8 weeks on an HCD as compared to mice reconstituted with Cd79a +/+ BM (data not shown), indicating that deletion of one Cd79a allele does not alter the T FH response or the development of atherosclerosis. Moreover, irradiated Ldlr −/− mice that had been maintained on a chow diet for 8 weeks did not display an increased percentage of splenic T FH cells (0.54 ± 0.057%) in comparison to Ldlr −/− mice fed an HCD, indicating that an HCD is required for induction of a T FH response. Notably, MZB cell deficiency did not accelerate the development of atherosclerosis in the absence of CD4 + T cells (Fig. 2c) . Furthermore, selective T FH cell depletion using an anti-ICOSL neutralizing antibody ( Supplementary Fig. 2h-k) abrogated the acceleration of atherosclerosis in MZB cell-deficient mice (Fig. 2d) , highlighting the role of the T FH cell response in the proatherogenic phenotype caused by MZB cell deficiency.
An HCD activates a homeostatic and anti-inflammatory program in MZB cells
As modulation of T FH responses by MZB cells has not been described previously, we used an unbiased approach to gain mechanistic insight. After sorting MZB cells from Ldlr −/− mice following 8 weeks on a chow diet or an HCD and performing RNA-seq, we found that 71 genes were significantly upregulated and 21 genes were significantly downregulated (P < 0.0004, q < 0.01 for all up-and downregulated genes) in MZB cells after an HCD (Fig. 3a,b Scale bars, 500 µm. For a-c, a two-tailed unpaired Student's t-test or two-way ANOVA was used for statistical analysis: *P < 0.05, **P < 0.01.
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). Intriguingly, we also found a marked induction of pathways that are critical for the maintenance of metabolic and immune homeostasis, notably the NF-κB (Tnfaip3, Nfkbid, Atf3, Nr4a1, Dusp1 and Dusp4) and AP1 (Fos, Jun, Atf3, Crem, Dusp1 and Dusp4) pathways.
ATF3 expression in MZB cells controls T FH cell accumulation in response to an HCD and is required for the atheroprotective effect of MZB cells The gene encoding ATF3, a member of the CREB/ATF family of transcription factors, was the most highly upregulated transcription factor gene in MZB cells after an HCD (Fig. 3a) , and bioinformatic analysis indicated that ATF3 could potentially link several pathways downstream of innate and adaptive immune receptors (Fig. 3c,d ). ATF3 regulation of metabolic and immune pathways is well documented in cell types other than B cells, most notably in macrophages. In response to lipid loading, ATF3 suppresses the transcription of Ch25h, which encodes cholesterol 25-hydroxylase, an enzyme that converts cholesterol into 25-hydroxycholesterol, thereby limiting foam cell formation 20 . In response to stimulation with HDL cholesterol or activation of Toll-like receptor 4 (TLR4), which can be triggered by macrophage treatment with oxidized LDL (oxLDL) or free fatty acids, ATF3 interacts with NF-κB1 and AP1 to induce a major negative feedback loop and shut down proinflammatory responses 21, 22 . These regulatory functions of ATF3 are consistent with our finding that Atf3 upregulation in MZB cells after an HCD was accompanied by negative regulation of TLR signaling (analysis with Ingenuity software, P = 1.38 × 10 −3 ) (Fig. 3c) . Moreover, we found that the NF-E2-related factor 2 (NRF2)-mediated oxidative stress response was the most significantly activated Ingenuity canonical pathway in MZB cells after an HCD (P = 3.02 × 10 −4 ) (Fig. 3c) , which is consistent with a previous report that Atf3 is strongly induced by NRF2 in response to reactive oxygen species 23 . Thus, our data suggest a potentially dominant role for ATF3 in orchestrating the regulatory program induced in MZB cells after an HCD.
The function of ATF3 in B lymphocytes is unknown. Because an HCD increases the level of circulating endotoxin in mice (Supplementary Fig. 3a ) and humans (reviewed in ref. 24) , we analyzed the response of wild-type (WT) and Atf3 −/− MZB cells to lipopolysaccharide (LPS). Il6 is a prototypical TLR4-induced inflammatory gene that is directly repressed by ATF3 in macrophages 21, 22 . We found that ATF3 similarly limited Il6 expression in LPS-treated MZB cells (Fig. 4a) . We also found that ATF3 deficiency in MZB cells prevented LPS-induced upregulation of both gene and protein expression of PDL1 (encoded by Cd274) (Fig. 4b,c) , a ligand for PD1 (encoded by Pdcd1) and a potential regulator of the T FH response 25 . To examine the impact of ATF3 deficiency in MZB cells on the immune response in vivo to an HCD, we reconstituted lethally irradiated Ldlr −/− mice with BM from Cd79a Cre/+ ; Rbpjk flox/flox mice (the 'no MZB' group) and compared them to Ldlr −/− mice reconstituted with mixed BM containing 80% Cd79a Cre/+ ; Rbpjk flox/flox BM and either 20% WT BM (the 'WT MZB' group) or 20% Atf3 −/− BM (the 'Atf3 −/− MZB' group) (Online Methods). As expected, MZB cells were completely absent in the no-MZB group and were fully reconstituted in the WT MZB and Atf3 −/− MZB groups ( Supplementary  Fig. 3b ). In accordance with the in vitro data, PDL1 expression was markedly reduced on reconstituted Atf3 −/− MZB cells in comparison to WT MZB cells (Fig. 4d,e) . Reconstitution of MZB-deficient mice with WT MZB cells significantly reduced the accumulation of T FH and GC B cells in the spleen (Fig. 4f,g ) and fully rescued the accelerated atherosclerosis phenotype caused by MZB cell deficiency (Fig. 4h,i) , despite not having effects on plasma cholesterol levels ( Supplementary Fig. 3c ) or plaque composition ( Supplementary  Fig. 3d,e) . However, reconstitution with Atf3-deficient MZB cells was unable to limit the proatherogenic T FH -GC response of MZB cell deficiency (Fig. 4f-i 
MZB cells limit T FH cell motility through upregulation of PDL1
We next examined whether a direct interaction between MZB and T cells is required to limit the T FH response. We hypothesized that MZB cells may need to migrate to the splenic follicle in order to interfere with T FH cells. MZB cells continuously shuttle between the marginal zone and the follicle, and CXCR5 expression on MZB cells is required to induce their translocation into the follicle upon downregulation of S1PR1 (ref. 26). We therefore reconstituted Ldlr −/− MZB cell-deficient mice with Cxcr5 −/− or WT MZB cells (Online Methods). MZB cell reconstitution was similar for the Cxcr5 −/− and WT MZB groups (7.42 ± 1.68% and 6.81 ± 0.64%, respectively; n = 8 in each group). In contrast to our expectation, Cxcr5 deletion in MZB cells did not impair their ability to reduce T FH cell accumulation (3.52% and 3.54% in the WT and Cxcr5 −/− MZB cell groups, respectively; n = 8 in each group), suggesting that MZB cell shuttling to the follicle is not required for the inhibitory role of MZB cells on T FH cell accumulation. We therefore hypothesized that MZB cells may exert their control on the T FH response by interacting with pre-T FH cells in the T cell zone or at the T-B border of the spleen before T FH translocation into the follicle. B cell movement into the T cell zone and to the T-B border requires the coordinated actions of the CCR7 and EBI2 receptors (reviewed in refs. 27,28). Cell-sorted MZB cells, but not FOB cells, recovered from Ldlr −/− mice showed increased expression of Ccr7 and Ebi2 in response to an HCD as compared to a chow diet (Supplementary Fig. 4a,b) , suggesting that an HCD might promote MZB cell movement into the T cell zone and the T-B border 27, 28 . In accordance with this hypothesis, we found that an HCD led to increased accumulation of IgM hi MZB-like cells at the boundary of the T cell zone where IgM hi B cells established close cell-cell contacts with CXCR5 + CD4 + T cells (Supplementary Fig. 4c,d) .
We next sought to test whether physical interaction of MZB and T FH cells is required for downregulation of the T FH response. In studying the interaction between MZB and T FH cells, we focused on the PDL1-PD1 axis for several reasons. MZB cells expressed the highest level of PDL1 of the B cell subsets tested (Supplementary Fig. 5a ), and we noted in the RNA-seq data that an HCD led to upregulation of Cd274 expression in MZB cells, a finding that was confirmed by qPCR and cell surface expression data (Fig. 5a) . Notably, in FOB cells, an HCD led to upregulation of Icosl but not Cd274 (Fig. 5b) , which is of interest in the context of previous findings showing that ICOS and PD1 signaling have contrasting roles in T FH cells; the former is required to instruct T FH cell differentiation (reviewed in ref. 29) , whereas the latter limits the number of T FH cells and regulates the survival of GC B cells 25 .
When we cultured, sorted and labeled T FH cells in vitro with cellsorted MZB or FOB cells (all from immunized WT mice; Online Methods), we found that co-culture with MZB cells resulted in significantly lower levels of T FH cell velocity and motility as compared to co-culture with FOB cells (Fig. 5c,d) . Moreover, contact time and the number of T FH cells interacting with B cells were significantly higher when T FH cells were co-cultured with MZB as compared to FOB cells (Fig. 5e ). These differences were abrogated when a blocking anti-PDL1 antibody was added to the co-culture (Fig. 5c-e) , indicating that the inhibitory effect of MZB cells on T FH cells relies on PDL1. Our results are consistent with previous work that reported PD1-dependent immune exhaustion through induction of antiviral T cell motility paralysis 30 . In another experiment, we found that incubation Centroid y (µm) For a-h, a two-tailed unpaired Student's t-test was used for statistical analysis: *P < 0.05, **P < 0.01, ***P < 0.001. Fig. 5b,c) , which is consistent with upregulation of PDL1 expression in MZB cells after an HCD.
(d,e) Quantification of the T cell centroid velocity (µm/min) (d) and contact time (s) between T FH and MZB or FOB cells (e) (each symbol represents one T FH -B cell interaction; horizontal bars denote the mean ± s.e.m.). (f-h) Percentages of T FH cells (f) and GC B cells (g) in
BCR signaling promotes PDL1 expression in MZB cells
We were interested in the high expression of PDL1 on MZB as compared to FOB cells. These B cell subsets may differ in BCR signaling strength, and the BCR signaling pathway was altered in MZB cells after an HCD. We found that direct engagement of IgM on purified MZB cells increased both gene and protein expression of PDL1, and these effects were dependent on BTK activation ( Supplementary  Fig. 6a-d) . We next examined human circulating MZB-like cells 31, 32 and found that they expressed higher levels of PDL1 than circulating naive B cells (Supplementary Fig. 6e) . Stimulation of BCR signaling further induced PDL1 expression in these human MZB-like cells (Supplementary Fig. 6f,g ). We also noted that human splenic MZB cells 31, 32 expressed much higher levels of PDL1 than naive splenic B cells (Supplementary Fig. 6h ). We conclude that both murine and human MZB cells show comparatively high levels of PDL1 expression when compared to other B cell populations and that PDL1 expression in MZB cells is regulated by BCR signaling.
MZB cells control the proatherogenic T FH -GC response through upregulation of PDL1
To address the direct role of MZB cell-restricted PDL1 expression in modulation of the T FH -GC response in vivo, we reconstituted MZB cell-deficient Ldlr −/− mice with WT or Cd274 −/− MZB cells (Online Methods). Similar levels of MZB cell reconstitution were achieved in the two groups of mice (Supplementary Fig. 7a ). As expected, PDL1 expression was almost completely abrogated on reconstituted MZB cells in the Cd274 −/− MZB group as compared to the WT MZB group (Supplementary Fig. 7b) . Strikingly, reconstitution of Ldlr −/− mice with Cd274-deficient MZB cells was unable to limit the T FH -GC response to an HCD (Fig. 5f,g ), such that the Cd274 −/− MZB group had more severe atherosclerosis than the WT group ( Fig. 5h and Supplementary Fig. 7c-g ), providing evidence that PDL1 expression in MZB cells limits the proatherogenic T FH response.
MZB cell deficiency alters the T FH cell program
We were surprised by the absence of a clear increase in antibody levels ( Supplementary Fig. 1k-n) despite the increased numbers of T FH cells in MZB cell-deficient mice after an HCD. This finding is reminiscent of the effects of PD1 deficiency in T cells 25 , which led to an increase in T FH cell numbers but an impairment of T FH quality; in particular, PD1-deficient T FH cells had reduced production of IL-21, a cytokine that is required for optimal antibody responses 33 . This previous work fits with our identification of a major role of MZB cell-restricted PDL1 expression in regulation of the T FH response through interaction of PDL1 on MZB cells with PD1 on T FH cells.
To better characterize the T FH cells that develop in MZB celldeficient mice after an HCD, we performed RNA-seq on cell-sorted splenic T FH cells after 8 weeks on an HCD in lethally irradiated Ldlr −/− mice reconstituted with BM from Cd79a Cre/+ ; Rbpjk flox/flox mice (the no-MZB group) or from Cd79a +/+ ; Rbpjk flox/flox mice (the WT MZB group). We focused on the expression of a subset of genes associated with or directly involved in the determination of T FH cell identity. We did not find significant differences in the expression of Bcl6, Cxcr5 or Pdcd1 between the two groups, although we found a tendency toward reduced Bcl6 (P = 0.07) and Cxcr5 (P = 0.14) expression in the no-MZB group as compared to the WT MZB group. Notably, we found a significant reduction of Il21 expression in the no-MZB group (Fig. 6a,b) , supporting the hypothesis that the quality of T FH cells from MZB cell-deficient mice is impaired and providing a plausible explanation for the absence of an overt increase in antibody response, despite increased T FH cell numbers, in MZB cell-deficient animals. Further analysis of the RNA-seq data revealed differences in the expression of major transcription factors and pathways involved in the control of T FH cell differentiation between the two groups of mice (Fig. 6) : genes that limit the differentiation of T FH cells were upregulated in the no-MZB group, whereas pathways that promote T FH cell development were downregulated. For example, recent studies have identified an important role for KLF2 in limiting the differentiation of T FH cells through induction of S1pr1 (ref. 34) , and expression of both Klf2 and S1pr1 were significantly upregulated (at least twofold) in the no-MZB group (Fig. 6a,b) . In contrast to S1pr1, we found that expression of S1pr2, which supports T FH cell differentiation and promotes T FH cell retention in GCs 35 , was substantially reduced in the no-MZB group (Fig. 6a-d) . Decreased expression of S1PR2 in T FH cells is associated with decreased expression of Il21 but elevated expression of Ccr7, Ccr6, S1pr1 and Sell 35 , a pattern that we also observed in the no-MZB group (Fig. 6a) . Furthermore, expression levels of Icos, which downregulates Klf2 (ref. 36) , and of Maf, which promotes the expression of several T FH cell-related genes, including Il21 and Cxcr5 (ref. 37) , were both significantly downregulated in the no-MZB group (Fig. 6a,b,d) . Finally, expression of Ascl2, whose gene product interacts with BATF-IRF4 to orchestrate the T FH program through induction of CXCR5 and suppression of CCR7 expression and IL-2 signaling 38 , was significantly downregulated in the no-MZB group, along with Irf4, and expression of Ccr7 and Il2ra was upregulated (Fig. 6) . Differential regulation of Icos and Il2ra may control the bifurcation between effector helper T cell and T FH programs 39 , a concept that is in agreement with the over-representation of those pathways in the Ingenuity canonical pathway analysis of the RNA-seq data (Fig. 6c) .
DISCUSSION
Only a few previous studies have addressed the role of MZB cells in a hypercholesterolemic context 16, 40 . MZB cell abundance increases in the spleens of hypercholesterolemic Apoe −/− mice in comparison to WT animals owing in part to decreased interferon (IFN)-γ release by invariant natural killer T (iNKT) cells 40 . MZB cells also ingest modified LDL and mount extrafollicular antibody responses against oxidationspecific epitopes 16 . However, to our knowledge, the contribution of MZB cells to atherosclerosis has not previously been explored. Our results identify a critical role for MZB cells in the establishment of an optimal T FH program in response to an HCD, limiting exaggerated adaptive immune responses and substantially halting the development and progression of atherosclerosis.
These findings raise several important questions that require further exploration. For example, what signals activate MZB cells after an HCD? Our RNA-seq data point to the involvement of the TLR and BCR signaling pathways. One potential factor leading to MZB cell activation after an HCD is diet-induced translocation of endotoxin from the gut to the circulation, but there are many other possibilities, including activation by oxidation-specific epitopes from modified self proteins and lipids and the direct or indirect impact of the gut microbiota. In this regard, a recent study reported induction of regulatory B cells by gut-microbiotadriven IL-1β and IL-6 (ref. 41 ). Thus, a better understanding of the major determinants of MZB cell activation after HCD is needed.
In view of our findings that, in HCD-fed mice, MZB cells leave the marginal zone and interact with pre-T FH cells, it will be important to study the signals that instruct MZB cells to leave the marginal zone and guide them to T FH cells. In this regard, we did not observe downregulation of S1pr1 expression or increased expression of Cxcr5, the major receptors that control the shuttling of MZB cells between the marginal zone and the follicle 26 . Moreover, Cxcr5 deletion in MZB cells did not alter their ability to regulate the T FH cell response. Our data point to other possible mechanisms; for example, as expression of Cd69, which suppresses the function of S1PR1 (ref. 42) , was highly upregulated in MZB cells after HCD, it may be responsible for MZB cell egress from the marginal zone. On the other hand, MZB cells after HCD also upregulate CCR7 and EBI2, the latter of which is a receptor for oxysterols 43, 44 ; therefore, CCR7 and EBI2 may facilitate MZB cell movement to the T cell zone and the T-B border, respectively.
Our findings indicate that PDL1 expression in MZB cells regulates T FH cell motility through induction of PD1 signaling in pre-T FH cells. Previous work has unraveled a critical role for ICOSL expression on FOB cells in ICOS-driven T cell motility at the T-B border, whereby FOB cells promote the recruitment of T FH cells into the follicle 45 . In this regard, the differential upregulation of Cd274 and Icosl in MZB as compared with FOB cells suggests that FOB and MZB cells have contrasting roles in response to HCD: FOB cells promote T FH cell development, whereas MZB cells shut down any exaggerated activation of the T FH response.
Our results agree with previous studies that reported increased proatherogenic T cell responses in mice with combined deficiency of PDL1 and PDL2 (ref. 46) or impairment of PD1 (ref. 47 ). However, the mechanisms proposed in these previous studies differed and were attributed mainly to macrophage-or dendritic cell-dependent alteration of T cell activation. Our results substantially extend these previous findings by identifying PDL1 expression in MZB cells as a major regulator of the proatherogenic T FH response. Our results are also in agreement with a recent study that reported regulation of T FH cells by B cells expressing high levels of PDL1 in a setting of experimental autoimmune encephalomyelitis 48 . However, the specific role of MZB cells in the regulation of immune responses in this context was not reported.
Our work identifies a determinant role for MZB cells in regulation of the T FH cell program, but additional work will be required to fully address the mechanisms through which MZB cells control T FH cell differentiation. For example, expression of the transcription factor BLIMP1 was downregulated in the T FH cells of MZB cell-deficient mice. As this transcription factor is an antagonist of BCL6 and a major inhibitor of T FH differentiation 49 , it will be interesting to study the mechanisms underlying its downregulation. Although PD1 signaling in T FH cells has been reported to regulate follicular regulatory T cells in blood and lymph nodes 50 , we did not find an effect of MZB cell deficiency on Foxp3 expression in T FH cells (data not shown), suggesting little or no effect of MZB deficiency on regulatory T FH cells. However, we did detect reduced expression of Ctla4 in the T FH cells of MZB cell-deficient animals, suggesting an increased susceptibility of T FH cells to activation, which is consistent with the increased number of effector memory T cells in the absence of MZB cells in the spleen.
Our work did not address the mechanisms through which T FH cells promote atherogenesis when released from the negative regulatory influence of MZB cells. The changes caused by MZB cell deficiency in the levels of circulating antibodies directed against oxidation epitopes were variable and did not correlate with acceleration of atherosclerosis. However, a more detailed assessment of the humoral response in MZB cell-deficient mice should be carried out before reaching any definite conclusions about the contribution of the GC response to the atherosclerotic phenotype of these mice.
In conclusion, this work reveals a new role for MZB cells in maintaining immune homeostasis in response to HCD through activation of a regulatory program affecting both the quantity and quality of T FH cells. MZB cells appear to be required for optimal T FH cell differentiation while restraining the T FH response. Absence of MZB cells leads to excessive accumulation of suboptimally differentiated T FH cells and increased levels of helper T and T effector memory cells. These results may have important implications for understanding of the impact of environmental influences, such as variations in diet composition, on the initiation and/or progression of immunemediated diseases.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. performed using the Ovation Rapid DR Library System (NuGEN). The barcoded libraries were combined and loaded onto an Illumina HiSeq 2500 system for single-end 50-bp sequencing at the Genomics Core Facility, Cambridge Institute, CRUK. The sequencing yielded 213 million reads, and the reads were aligned onto the mouse GRCm38 genome using TopHat 2.0.11 (ref. 55); the average mapping rate was 93.5%. Gene abundance and differential expression were determined with Cufflinks 2.2.1 (ref. 56) and are expressed in fragments per kilobase per million mapped reads (FPKM). Genes with a linear fold change in expression of >1.5-fold in FPKM and a Benjamini-Hochberg false discovery rate <10% were considered to be differentially expressed.
Quantitative RT-PCR. For gene expression analysis, RNA from sorted MZB, FOB and T FH cells was isolated using an RNAeasy mini kit (Qiagen). RT-PCR was performed using a QuantiTect Reverse Transcription kit (Qiagen) or a QuantiTect Whole-Transcriptome kit, depending on the yield of the mRNA. qRT-PCR was performed with SYBR Green primers. Primer sequences are listed in Supplementary Table 2. Statistical analysis. Values are expressed as means ± s.e.m. Based on pilot experiments, we found that MZB cell deficiency increased lesion size by twofold. Using the equation for Student's t-test for a difference of 2 means gives n = 6 for the detection of a 50% increase in lesion size with α = 0.05 and 90% power. Where data sets passed normality tests, differences between values were examined using the parametric two-tailed unpaired Student's t-test or two-way ANOVA; other data sets were examined using the non-parametric Mann-Whitney U test and differences were considered significant at P < 0.05. Hypergeometric enrichment analysis of canonical pathways within the differentially regulated gene set was carried out using Ingenuity Pathway Analysis (Qiagen).
Data availability. The data for the findings of this study are available from the corresponding author upon reasonable request. MZB cell and T FH cell RNA-seq data are available at the Gene Expression Omnibus (GEO) under accession GSE71699. 
